Vacuna frente al virus del papiloma humano y cribado de cáncer de cuello de útero

Progresos de Obstetricia y Ginecología - Tập 52 Số 6 - Trang 361-369 - 2009
Javier Cortés1, Eduardo Vilaplana Vilaplana2, Pilar Miranda3, Gabriel Ferret4, Daniel Andı́a5, José Manuel Ramón y Cajal6, José Antonio Vidart7
1Coordinador del Grupo Español de Vacuna VPH.
2Ginecología Oncológica. Instituto Bernabeu. Alicante. España.
3Servicio de Ginecología y Obstetricia, Hospital de Fuenlabrada, Madrid, España
4Ginecología y Obstetricia. Policlínica Miramar. Palma de Mallorca. Illes Balears. España.
5Servicio de Ginecología y Obstetricia. Hospital de Basurto. Bilbao. España.
6Servicio de Ginecología y Obstetricia. Hospital de San Jorge. Huesca. España.
7Servicio de Ginecología y Obstetricia. Hospital Clínico. Madrid. España.

Tóm tắt

Từ khóa


Tài liệu tham khảo

Garnett, 2006, Modelling the impact of HPV vaccines on cervical cancer and screening programmes, Vaccine, 24, 178, 10.1016/j.vaccine.2006.05.116

Sesión 5B de la 24th Internacional Papillomavirus Conference and Clinical Workshop (IPCCW). Beijing, China, noviembre 3-9, 2007.

European Centre for Disease Prevention and Control (ECDC) Factsheet on HPV Vaccines. January 22, 2008, 1-3.

Harper, 2008, Substained immunogenicity and high efficacy against HPV-16/18 related cervical neoplasia: Long-term follow-up through 6,4 years in women vaccinated with Cervarix (GSK,s HPV 16/18 AS04 candidate vaccine), Gynecol Oncol, 109, 158

2007, Efficacy of a prophylactic adjuvanted bivalent L1 viruslike particle against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial, Lancet, 369, 2161, 10.1016/S0140-6736(07)60946-5

Elmar Joura for the FUTURE I and II Study Group: Sustained protection by quadrivalent HPV (type 6, 11, 16, 18) vaccine through 4 years against HPV 6/11/16/18-related cervical intraepithelial neoplasia grade 2/3 and adenocarcinoma (AIS) of the cervix International Congress on Anti Cancer Treatment, 5-8 de febrero de 2008, París.

Jenkins, 2008, A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention, Gynecol Oncol, 110, S18, 10.1016/j.ygyno.2008.06.027

Ficha técnica Gardasil®. Septiembre 2008. Disponible en www.emea.europa.eu/humandocs/PDFs/EPAR/gardasil/H-703-PI-es.pdf

Agosti, 2007, Introducing HPV vaccine in developing countries. Key challenges and issues, N Engl J Med, 356, 1908, 10.1056/NEJMp078053

Smith, 2007, HPV type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis up-date, Int J Cancer, 121, 621, 10.1002/ijc.22527

Pretet, 2008, Human papillomavirus (HPV) distribution in invasive cervical cancers in France: EDITH study, Int J Cancer, 122, 428, 10.1002/ijc.23092

WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Summary report on HPV and cervical cancer statistics in Spain, 2007. [Accedido 28 Oct 2008]. Disponible en: http://www.who.int/ hpvcentre

Kulasingam, 2007, Potential effects of decreased cervical cancer screening participation after HPV vaccination: an example from the U.S, Vaccine, 25, 8110, 10.1016/j.vaccine.2007.09.035

Kevin, 2007, Efficacy of a prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials, Lancet, 369, 1861, 10.1016/S0140-6736(07)60852-6

Van der Aa, 2008, Does lowering the screening age for cervical cancer in The Netherlands make sense?, Int J Cancer, 123, 1403, 10.1002/ijc.23652

Huh WK. Presentado en el 39th Annual Meeting on Women's Cancer. Society of Gynecologic Oncologists. Tampa, USA, 9-12 de marzo de 2008.

Disponible en: http://www.ine.es/inebase/cgi/axi

Puig-Tintoré, 2008, Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain, J Low Genit Tract Dis, 12, 82, 10.1097/LGT.0b013e3181599c16

Vilaplana, 2006, Encuesta Española sobre Resultados Citológicos Anómalos, Boletín de la AEPCC, 20, 19

Castellsagué, 2008, Impacto de la vacuna tetravalente frente al virus del papiloma humano (VPH 6, 11, 16, 18) en las enfermedades asociadas a VPH en España, Prog Obstet Ginecol, 51, 520, 10.1016/S0304-5013(08)72326-4

Peto, 2004, The cervical cancer epidemic that screening has prevented in the U.K, Lancet, 364, 249, 10.1016/S0140-6736(04)16674-9

Mayrand, 2007, Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer, N Engl J Med, 357, 1579, 10.1056/NEJMoa071430

Cuzick, 2006, Overview of the European and North American studies on HPV testing in primary cervical cancer screening, Int J Cancer, 19, 1095, 10.1002/ijc.21955

De Sanjosé, 2007, Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis, Lancet Infect Dis, 7, 453, 10.1016/S1473-3099(07)70158-5

Kahn, 2005, The elevated 10-year risk of cervical precancer and cancer in women with HPV type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice, J Natl Cancer Inst, 97, 1072, 10.1093/jnci/dji187

Heideman, 2008, Vaccination against HPV: indications for women and the impact on the cervical screening programme, BJOG, 115, 938, 10.1111/j.1471-0528.2008.01779.x

Goldhaber-Fiebert, 2008, Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination, J Natl Cancer Inst, 100, 290, 10.1093/jnci/djn019

Derchain, 2008, Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in high-risk population: experience from the LAMS study, J Med Screen, 15, 97, 10.1258/jms.2008.007061

Dillner, 2008, Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening, BMJ, 337, 1754, 10.1136/bmj.a1754

Cortés J, Alba A, Andía D, Ramón y Cajal JM, Velasco J y Vilaplana E. Grupo de Trabajo Vacuna VPH y Cribado. I Foro Español sobre Vacuna VPH. Sevilla, 12 de junio de 2008.

Roden, 2007, Reemplazo de genotipos del VPH tras la vacunación, HPV Today (ed. esp.), 11, 8

Cortés, 2005, Estrategias de cribado del cáncer de cuello uterino, Prog Obstet Ginecol, 48, 228

Council of the European Union. Council Conclusions on Reducing the Burden of Cancer. 2876th Employment, social policy, health and consumer affairs Council Meeting. Luxembourg, 10 June 2008.

Lazcano-Ponce, 2008, Decreasing cervical cancer mortality in mexico: effect of Papanicolaou coverage, birthrate and the importance of diagnostic validity of cytology, Cancer Epidemiol Biomarkers Prev, 17, 2808, 10.1158/1055-9965.EPI-07-2659

WHO. Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. Geneva, 2001.

Diaz, 2008, Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India, Br J Cancer, 99, 230, 10.1038/sj.bjc.6604462

Gakidou, 2008, Coverage of Cervical Cancer Screening in 57 Countries: Low Average Levels and Large Inequalities, E PLoS Med, 5, e132, 10.1371/journal.pmed.0050132

Chesson, 2008, Costeffectiveness of HPV vaccination in the United States, Em Infect Dis, 14, 244, 10.3201/eid1402.070499

Bergeron, 2008, Costeffectiveness analysis of the introduction of a quadrivalent HPV vaccine in France, Int J Technol Assess Health Care, 24, 10, 10.1017/S0266462307080026

Kim JJ. Human papillomavirus vaccination in the UK. BMJ Research. doi: 10.1136/bmj.a769

Kim, 2008, Health and Economic implications of HPV Vaccination in the United States, N Engj J Med, 359, 821, 10.1056/NEJMsa0707052

Insinga RP, Dasbach EJ, Shanon E, Allen PD, Myers ER. Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccination: the FUTURE Study Economic Evaluation. 2008, International Society for Pharmacoeconomics and Outcomes Research (ISPOR), 1098-3015/08.

[Accedido 25 Oct 2008] Disponible en: http://www.ine.es/prensa/np495.pdf

López, 2007, Estudio de coste-efectividad de la vacuna tetravalente del papiloma humano, Rev Esp Econ Salud, 6, 400

Langeron, 2008, Análisis de coste-efectividad de la vacunación frente al virus del papiloma humano tipos 6, 11, 16 y 18 en España, Vacunas, 9, 3, 10.1016/S1576-9887(08)71915-0